Barclays analyst Gena Wang lowered the firm’s price target on Sarepta to $203 from $226 and keeps an Overweight rating on the shares. The company’s Q2 missed on both total and Elevidys revenue, the analyst tells investors in a research note. The firm says Sarepta’s key pipeline programs are on track with SRP-9003 pivotal data likely in Q1 of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT: